Last reviewed · How we verify
Ambrisentan Pill
At a glance
| Generic name | Ambrisentan Pill |
|---|---|
| Also known as | Letairis |
| Sponsor | Ochsner Health System |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Mechanisms of Cerebrovascular Control (PHASE1)
- Ambrisentan for the Improvement in Right Ventricular Strain in Scleroderma Associated Pulmonary Arterial Hypertension (NA)
- Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan (PHASE4)
- The Role of Endothelin-1 in Sickle Cell Disease (PHASE1)
- The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study (PHASE4)
- Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension (PHASE4)
- Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension (PHASE3)
- Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ambrisentan Pill CI brief — competitive landscape report
- Ambrisentan Pill updates RSS · CI watch RSS
- Ochsner Health System portfolio CI